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Background: Usher syndrome, a combination of retinitis
pigmentosa (RP) and sensorineural hearing loss with or without
vestibular dysfunction, displays a high degree of clinical and
genetic heterogeneity. Three clinical subtypes can be distin-
guished, based on the age of onset and severity of the hearing
impairment, and the presence or absence of vestibular
abnormalities. Thus far, eight genes have been implicated in
the syndrome, together comprising 347 protein-coding exons.
Methods: To improve DNA diagnostics for patients with Usher
syndrome, we developed a genotyping microarray based on
the arrayed primer extension (APEX) method. Allele-specific
oligonucleotides corresponding to all 298 Usher syndrome-
associated sequence variants known to date, 76 of which are
novel, were arrayed.
Results: Approximately half of these variants were validated
using original patient DNAs, which yielded an accuracy of
.98%. The efficiency of the Usher genotyping microarray was
tested using DNAs from 370 unrelated European and
American patients with Usher syndrome. Sequence variants
were identified in 64/140 (46%) patients with Usher syndrome
type I, 45/189 (24%) patients with Usher syndrome type II, 6/
21 (29%) patients with Usher syndrome type III and 6/20 (30%)
patients with atypical Usher syndrome. The chip also identified
two novel sequence variants, c.400C.T (p.R134X) in PCDH15
and c.1606T.C (p.C536S) in USH2A.
Conclusion: The Usher genotyping microarray is a versatile
and affordable screening tool for Usher syndrome. Its efficiency
will improve with the addition of novel sequence variants with
minimal extra costs, making it a very useful first-pass screening
tool.
P
atients with Usher syndrome (MIM 276900-2,
MIM 276905, MIM 605472) have autosomal recessive
retinitis pigmentosa (arRP) and sensorineural hearing
impairment. In addition, vestibular dysfunction can be seen
in a subset of patients. Usher syndrome occurs in ,1/20 000
individuals and represents 50% of all cases with deafblind-
ness.1–3 Three clinical subtypes can be distinguished.4 Patients
with Usher syndrome type I (USH1) show severe to profound
congenital hearing loss, RP and vestibular areflexia. Patients
with Usher syndrome type II (USH2) have moderate to severe
hearing loss, RP and normal or variable vestibular function
(Huygen et al, unpublished data). Usher syndrome type III
(USH3) patients present with progressive hearing loss, RP and
variable vestibular function. The eight genes known to be
involved in Usher syndrome are CDH23, MYO7A, PCDH15,
USH1C and USH1G for USH1, USH2A and VLGR1 for USH2, and
USH3A for USH3.5–15 The USH2A gene is also implicated in
arRP.16–18 Likewise, mutations in CDH23, MYO7A, PCDH15 and
USH1C have been reported in patients with non-syndromic
hearing impairment.7 12 19–22
Identification of the causal mutations is important for the
early diagnosis of Usher syndrome, which is relevant for the
decision whether or not to elect for a cochlear implant, for
genetic counselling and for prenatal diagnosis. In addition,
gene-specific treatments might become available in the near
Abbreviations: APEX, arrayed primer extension; arRP, autosomal
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Key points
N We developed a genotyping microarray for Usher
syndrome based on the arrayed primer extension
(APEX) method, which includes 298 Usher syndrome-
associated sequence variants identified in eight genes.
Seventy six variants have not been reported previously.
N Validation of half of these variants employing DNAs from
the original Usher syndrome patients yielded a micro-
array accuracy of .98%. The efficiency of the micro-
array was analysed using DNAs from 370 novel
unrelated Usher syndrome patients. Sequence variants
were identified in 46% of patients with Usher syndrome
type I, 24% of patients with Usher syndrome type II, 29%
of patients with Usher syndrome type III and 30% of
patients with atypical Usher syndrome.
N We conclude that this genotyping microarray represents
a versatile and affordable screening tool for Usher
syndrome. Its efficiency will improve with the addition of
novel sequence variants with minimal extra costs, making
it a very useful first-pass screening tool.
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future, necessitating knowledge of the underlying gene defect.
Comprehensive molecular diagnostics for Usher syndrome has
been hampered both by the genetic heterogeneity and the large
number of exons for six of the eight known Usher genes. The
five USH1 genes collectively contain 179 protein-coding exons,
the two USH2 genes comprise 162 protein-coding exons, and
the USH3 gene USH3A has six protein-coding exons, some of
which are alternatively spliced (UCSC Human Genome Browser
at http://genome.cse.ucsc.edu). Thus far, large-scale mutation
screening has been carried out using single strand conforma-
tion analysis and denaturing gradient gel electrophoresis, with
subsequent sequence analysis of fragments with an aberrant
migration pattern. For routine analysis, these techniques are
both time consuming and expensive.
In this study, we used microarray technology that was
previously used for efficient mutation analysis of the ABCA4
gene in patients with either autosomal recessive Stargardt
disease or autosomal recessive cone-rod dystrophy,23 24 as well
as for seven genes implicated in Leber congenital amaurosis
(LCA).25 26 It is inherent to the arrayed primer extension
(APEX) that it detects only known mutations and, therefore,
its efficiency is highly dependent on the extent of earlier
mutation analysis efforts. Here, we describe the first compre-
hensive Usher genotyping microarray which allows the
identification of known Usher gene defects in a high-
throughput and cost-effective manner.
METHODS
Patients
For validation purposes, we obtained genomic DNA from 158
patients with Usher syndrome in which the variants were
originally identified. In order to test the efficiency of the Usher
microarray (hereafter denoted ‘‘evaluation’’), 370 patients were
studied. Of these, 170 unrelated Usher syndrome patients were
ascertained in seven European countries: Belgium (20
patients), Denmark (10 patients), UK (34 patients), Germany
(27 patients), Italy (20 patients), Spain (5 patients),
Switzerland (7 patients) and the Netherlands (47 patients). A
further 200 patients from the USA (Boys Town, Omaha) were
ascertained. In total, we tested DNAs from 140 patients with
USH1, 189 patients with USH2, 21 patients with USH3 and 20
patients with atypical Usher syndrome (USHA). The patients,
except for 104 USH2 patients from the USA who were
previously shown not to carry the USH2A c.2299delG
(p.E767fs) mutation, had not been previously tested for the
presence of Usher mutations. Research procedures were in
accordance with institutional guidelines and the Declaration of
Helsinki. Informed consent was obtained at each centre from
all patients after the nature of procedures to be performed was
fully explained.
Molecular methods
Microarrays were designed and manufactured according to
arrayed primer extension (APEX) technology.27 28 A detailed
description of the methodology can be found elsewhere
(www.asperbio.com).29 30 In brief, 59-modified sequence-
specific oligonucleotides are arrayed on a glass slide. In general,
these oligonucleotides are designed with their 39 end immedi-
ately adjacent to the variable site. PCR-amplified and fragmen-
ted target nucleic acids are annealed to oligonucleotides on the
slide, followed by sequence-specific extension of the 39 ends of
primers with dye-labelled nucleotide analogues (ddNTPs) by
DNA polymerase. The APEX reaction is, in essence, a sequen-
cing reaction on a solid support.
A total of 120 amplicons from eight genes (table 1) were
amplified as described previously.23 Primer sequences are
available on request. In the amplification mixture, 20% of the
dTTP was substituted by dUTP.29 The amplification products
were concentrated and purified (GENErALL PCR kit; General
Biosystems, Seoul, Korea). The fragmentation of amplification
products was achieved by adding thermolabile uracil N-
glycosylase (Epicenter Technologies, Madison, WI) and heat
treatment.29 One-sixth of every amplification product was used
in the primer extension reaction on the Usher microarray. Each
APEX reaction consisted of fragmented and pooled denatured
PCR products, 4 U Thermo Sequenase DNA Polymerase
(Amersham Biosciences, Little Chalfont, UK), 16 reaction
buffer and 1.4 mM final concentration of each fluorescently
labelled ddNTP: Texas Red-ddATP, fluorescein-ddGTP
(Amersham Biosciences), Cy3-ddCTP and Cy5-ddUTP (NEN,
Boston, Massachusetts, USA). The reaction mixture was
applied to a microarray slide for 15 min at 58 C˚. The reaction
was stopped by washing the slide at 95 C˚ in Milli-Q water.31 The
slides were imaged with the Genorama QuattroImager (Asper
Biotech, Tartu, Estonia) and the sequence variants were
identified by Genorama Genotyping software (Asper
Biotech).23 30
Array-identified variants were confirmed by direct sequen-
cing with the ABI PRISM Big Dye Terminator Cycle Sequencing
V2.0 Ready Reaction Kit and the ABI PRISM 3730 DNA
analyser (Applied Biosystems, Foster City, California, USA).
RESULTS
Construction of the Usher genotyping microarray
We compiled a list of 298 previously published and commu-
nicated sequence variants from the coding region and adjacent
intronic sequences of the eight Usher genes: CDH23, MYO7A,
PCDH15, USH1C, USH1G, USH2A, USH3A and VLGR1 (see
supplementary table 1 available at http://jmg.bmj.com/
supplemental). Intronic sequence variants were included when
they were predicted to affect splicing, that is, altering the
strictly conserved splice site sequences (nucleotides 22A or
21G of 39 splice sites; nucleotides +1G or +2T of 59 splice sites),
causing transversion of one or a few of the pyrimidines (25
through 214) of a 39 splice site, changing a 23C nucleotide of a
39 splice site, changing a +3, +4, +5 or +6 nucleotide of a 59
splice site, or exonic nucleotides being part of splice sites, to a
less favourable nucleotide. In addition, we included the
putatively benign sequence variants c.5156A.G (p.Y1719C) in
MYO7A and c.688G.A (p.V230M), c.1434G.C (p.E478D),
c.2052A.G (p.Q684Q, possible cryptic splice site), c.2137G.C
(p.G713R) and c.2522C.A (p.S841Y) in USH2A. Each sequence
variant was queried in duplicate by the software, from both
the sense and the antisense strand (Genorama Genotyping
software).
Table 1 Characteristics of Usher genes
Gene
Protein
coding
exons
Amplicons for
APEX analysis
Known
pathologic
variants
USH1
CDH23 69 32 52
MYO7A 48 39 118
PCDH15 32 6 7
USH1G 2 2 4
USH1C 28 6 8
USH2
USH2A 72 26 88
VLGR1 90 6 6
USH3
USH3A 6 3 9
Total 347 120 292
154 Cremers, Kimberling, Ku¨ lm, et al
www.jmedgenet.com
 group.bmj.com on April 13, 2012 - Published by jmg.bmj.comDownloaded from 
We also included four variants on the chip despite the fact
that there are inconsistencies in their notations in the original
publications or erroneous genomic sequence data: CDH23
c.3880.T (p.Q1294X),12 MYO7A c.269G.C (p.R90P),32 MYO7A
c.4039_4053del (p.R1347_F1351del),33 and USH2A c.233T.G
(p.F78V). The USH1C_ABCC8 122 815-bp deletion7 is not
represented on the chip.
Validation of the Usher genotyping microarray
We collected DNA samples from 158 patients with Usher
syndrome and at least one known variant. All variants, except
two, CDH23 c.3617C.G and MYO7A c.223delG, were reliably
identified. For the two unidentified variants (false negatives),
primers have been redesigned and will be retested (see
supplementary table 1 available at http://jmg.bmj.com/
supplemental). For the remaining 140 variants, no DNA
samples from the original patients were available as positive
controls. However, the wild-type sequences of these variants
were robustly identified. Since 102 of these variants represent
nucleotide substitutions, the identification of the wild-type
sequence can be regarded as a positive control since the same
25 mers are employed for the identification of both the wild-
type and mutant nucleotides. However, we cannot exclude the
possibility of erroneous sequence variant annotations, which
we observed for a number of mutations in the respective
original publications. Thirty eight non-validated variants
represent insertions/deletions for which in some instances
oligonucleotides linked to the microarray for detection of the
wild-type allele differed from that for detection of the mutant
allele.
Evaluation of the Usher genotyping microarray
The efficiency of the Usher microarray was evaluated using a
total of 370 patients: 140 USH1, 189 USH2, 21 USH3 and 20
USHA. The results are given both separately and combined for
the novel Usher patients from Europe and the USA (table 2).
The European patients originated from eight Western European
countries, that is, the Netherlands (12.7%), the UK (8.1%),
Germany (7.3%), Belgium (5.4%), Italy (5.4%), Denmark
(2.7%), Switzerland (1.9%) and Spain (1.4%). The majority of
the patients from the USA were of European descent. For
USH1, genotyping using the microarray revealed the highest
percentage of patients with either one or two mutations, 51%
for the European patients, 30% for the patients from the USA
and 46% when both groups are combined. When counting
mutated alleles, these percentages were 34%, 23% and 31%,
respectively. The best results were observed for the USH1
patients of Danish origin in whom a mutation was found in
80% (8/10) of cases or in 65% (13/20) of alleles.
For USH2 the percentages of patients with variants were
25%, 24% and 25%, respectively. The percentages for detected
USH2 alleles were 20%, 14% and 18%, respectively. A total of
104 of the patients with USH2 from the USA were pre-screened
for the p.E767fs mutation and patients heterozygous or homo-
zygous for this mutation were not included. This pre-screening
did not influence the genotyping detection rate for the
microarray which was 23% of the patients and 15% of the
alleles. The numbers of patients with USH3 or USHA were
relatively low. Consequently, the sensitivity of the microarray
for these patient groups, although rather good in the present
cohorts of patients, cannot be reliably assessed.
The USH2A variant c.2299delG (p.E767fs) was previously
described as a common mutation in Caucasian patients with
USH2, comprising between 13% and 39% of USH2A alleles.34–38
The genotyping presented here revealed a second common
mutation, c.11864G.A (p.W3955X) in exon 61 of this gene.
This nonsense mutation truncates the long isoform of the
USH2A protein.39 Three of 47 European patients with USH2
were heterozygous for this allele, twice in combination with
the p.E767fs mutation. In USH2 patients from the USA, 15
alleles with this mutation were detected in 13 of 142
patients. In total, 18 of 61 mutant alleles (30%) identified in
patients with USH2 were p.W3955X. However, since some of
the USH2 patients were pre-screened for the common p.E767fs
mutation, this percentage was probably higher than would be
expected in an unselected patient cohort. For the European
patients this percentage was only 16% (3/19). The p.W3955X
mutation was also heterozygously present in a patient with
USHA in whom the second mutation was not identified.
Haplotype analysis has to be performed to determine whether
the p.W3955X mutation is a founder mutation as has been
shown for p.E767fs.40
Table 2 Identification of Usher mutations in patients from Europe and the USA
Country
USH1 patients USH2 patients USH3 patients USHA patients
Total 0 all 1 all 2 alls Total 0 all 1 all 2 alls Total 0 all 1 all 2 alls Total 0 all 1 all 2 alls
Belgium, Germany, 51 27 12 12 35 25 5 5 3 3 0 0 5 4 1 0
and Netherlands
Switzerland 5 5 0 0 2 2 0 0
Italy, Spain 13 5 8 0 3 2 0 1 1 0 1 0 8 5 2 1
Denmark 10 2 3 5
UK 29 16 12 1 4 3 0 1 1 0 0 1
Total Europe 103 50 35 18 47 35 5 7 7 5 1 1 13 9 3 1
Patients with mutation 53/103 = 51% 12/47 = 25% 2/7 = 29% 4/13 = 31%
Mutant alleles 71/206 = 34% 19/94 = 20% 3/14 = 21% 5/26 = 19%
USA 37 26 5 6 38 29 7 2 14 9 3 1 7 5 1 1
Patients with mutation 11/37 = 30% 9/38 = 24% 4/14 = 29% 2/7 = 29%
Mutant alleles 17/74 = 23% 11/76 = 14% 5/28 = 18% 3/14 = 21%
Total 140 76 40 24 85 64 12 9 21 14 4 2 20 14 4 2
Patients with mutation 64/140 = 46% 21/85 = 25% 6/21 = 29% 6/20 = 30%
Mutant alleles 88/280 = 31% 30/170 = 18% 8/42 = 19% 8/40 = 20%
USA pre-screened 104 80 17 7
Patients with mutation 24/104 = 23%
Mutant alleles 31/208 = 15%
The number of cases with two alleles represent those cases for which two sequence variants were detected in the same gene. all, alleles.
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Of the mutations detected, 191 were re-evaluated by
sequence analysis and only two could not be confirmed (false
positives), which illustrates the robustness of the method. One
mutation, c.496+1G.A in the USH1C gene, was not detected by
the microarray but was detected afterwards by sequence
analysis (false negative). Segregation analysis could be per-
formed in relatives of 11 probands in whom at least two
variants were detected by chip analysis. In one of these families,
the analysis revealed that two CDH23 variants were present on
the same allele. For the remaining 10 probands the results are
compatible with both alleles each carrying one mutation.
Identification of novel variants in Usher genes
Since all four nucleotides are available during primer extension,
the APEX technology allows the detection of new nucleotide
variants for positions that were already known to be variant
and are represented by an assay on the microarray. In this way
two novel variants were detected and confirmed by sequence
analysis. In PCDH15, c.400C.T is predicted to cause the
nonsense mutation p.R134X. At this position the substitution
of a guanine for a cytosine was already described to cause the
missense mutation p.R134G in a family with non-syndromic
hearing loss.21 In the USH2A gene, a c.1606T.A was detected,
which is predicted to cause an amino acid substitution p.C536S.
The nucleotide substitution c.1606T.C (p.C536R) was reported
by Dreyer et al34 in one of 31 unrelated patients with USH2 who
also carried the p.E767fs variant.
Variants in genes known to be associated with a
different USH type
In a number of patients, variants were detected that did not
correspond with the type of Usher syndrome in the patient
(table 3). In five patients with USH1, one or two mutations
were detected in the USH2A gene. In USH2 patients, variants
were detected in the MYO7A gene and also in the USH3A gene,
and in USH3 patients variants were seen in MYO7A and in
USH2A. Whether the heterozygous mutations in the MYO7A
gene are indeed causative such that mutations in MYO7A can
also cause USH2 and USH3, remains to be determined. In many
cases, the clinical diagnosis may be ambiguous. This is also true
for the heterozygous USH2A mutations in patients with USH1
and USH3 and USH3A mutations in patients with USH2.
In patients with USHA, mutations were detected in MYO7A,
USH2A and CDH23 (table 3).
Variants identified in two Usher genes
In nine patients, variants in two different genes were detected,
that is, in four samples used for validation and in five patients
tested for evaluation of the chip (table 4). In three of the nine
cases, a variation in a second gene was present in addition to
two mutations in one of the other Usher genes. As segregation
analysis could not be performed for any of these cases, we
cannot conclude that they represent true digenic inheritance,
whether the variant in the second gene contributes to the
severity of the phenotype or whether the results are merely a
coincidence. However, in one of the cases with three sequence
variants, two in USH2A and one in MYO7A, the USH2A
mutations are protein truncating. These truncating mutations
are most likely sufficient to cause the disease and thus only a
modifying effect for the p.R1343S variant in MYO7A seems
plausible. A second case had two truncating mutations in
MYO7A in addition to p.P608R in USH1C. Also for this case, the
third variant might modify the phenotype but is not likely to be
primarily disease causing. The combination of variants in the
MYO7A and USH2A genes were seen in six of the eight cases
with variants in two Usher genes, which is not unexpected
since these genes are causative in the majority of the patients
with USH1 and USH2, respectively, and thus are expected to
exhibit the highest carrier frequencies.
USH variants with questionable pathogenicity
Several sequence variants in Usher genes have previously been
described for which pathogenicity was uncertain. A number of
these were included in the microarray and, based on the results
of the evaluation experiment, were regarded as polymorphisms.
Nine alleles with the missense variant p.E478D17 41 in the
USH2A gene were detected in patients with all three types of
Usher syndrome and in three patients, one of each with USH1,
USH2 and USH3, this variant was present in addition to two
pathogenic mutations. The frequency in controls was deter-
mined for the Jewish population (0/120 alleles).41 However, we
detected this variant in three out of 180 control alleles from the
Dutch population. The USH2A variant p.V230M was detected
nine times in patients with all three types of Usher syndrome.
In these patients, only one putative pathogenic USH2A
mutation was detected in addition to the p.V230M variant.
Dreyer et al34 did not detect this variant in controls, although
Jian Seyedahmadi et al17 detected similar frequencies in patients
and controls. The USH2A variant p.G713R was described by
Dreyer et al34 as likely to be pathogenic since it was not detected
in controls. However, Jian Seyedahmadi reported that the
variant did not co-segregate with the disease in some families.
In the present genotyping, the p.G713R variant was detected as
the only variant heterozygously in two patients with USH1 and
in one patient with USH3. In an USH2 patient it was detected
in addition to a truncating mutation. This variant was not
present in an affected sib of one of the USH1 patients. The
USH2A variant c.2052A.G (p.Q684Q)42 was described as
possibly creating a cryptic splice site. This nucleotide substitu-
tion was detected once in an USH2 patient as the only variant.
The USH2A variant p.S841Y was previously described to be
present in two of 186 control alleles.38 In the present genotyping
this variant was detected in one USH1 patient with one MYO7A
mutation and in one USH1 patient with one mutation in
CDH23.
Najera and co-workers questioned whether the variant
p.Y1719C in MYO7A was disease-causing33 since it was detected
Table 3 Variants in genes known to be associated with a
different USH type and variants associated with atypical
USH (USHA)
Patient Phenotype Allele 1 Allele 2
H2524 USH1 USH2A p.560fs
JD6381 USH1 USH2A p.E767fs
03-03704 USH1 USH2A p.L555V
57 USH1 USH2A p.R4115C
QUB4/B5 USH1 USH2A p.C536S USH2A p.H548S
D3900 USH2 USH3A p.N48K USH3A p.N48K
H2774 USH2 USH3A p.N48K
0303158 USH2 USH3A p.S50fs
D9569 USH2 MYO7A p.R1240Q
0401876 USH2 MYO7A c.736-3C.T
D8903 USH3 MYO7A p.Q1798X
D9804 USH3 MYO7A p.E1359fs
H2156 USH3 USH2A p.V218E
O2 USH3 USH2A p.E767fs
H0200 USHA MYO7A p.R1743W MYO7A p.R1743W
MM52 USHA MYO7A p.R1861X MYO7A p.R1861X
RP683 USHA CDH23 p.T1209A
21730 USHA CDH23 p.R1060W +
p.D1341N
T56 USHA USH2A p.L555V
H1362 USHA USH2A p.W3955X
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in 3/168 control alleles. We detected this variant in four
patients with all three different types of Usher syndrome,
two of whom did not have an additional variant in one of the
Usher genes. This does not support a causative effect of the
mutation.
DISCUSSION
A cost-effectiveness comparison of APEX mutation
analysis with other medium and high-throughput
mutation detection techniques
Routine mutation analysis of patients suffering from a
genetically heterogeneous disease has been severely hampered
by the high costs associated with application of conventional
analysis techniques for comprehensive mutation screening.
Despite the fact that most Usher syndrome patients can be
reliably grouped into one of two main clinical groups, a
systematic mutation analysis of either the USH1 or USH2 genes
still requires the analysis of 179 and 162 protein coding exons,
respectively. As depicted in table 5, the APEX-based mutation
detection array is an affordable and flexible system as new
alleles can be added without the need to design completely new
screening platforms. The main disadvantage is its low efficiency
in early versions since it relies on the extent of previous
mutation analysis studies performed using other techniques.
The Affymetrix resequencing technique has two disadvantages.
First, heterozygous deletions larger than 1 bp and all insertions
and duplications are missed because the complexity of the
microarray would increase disproportionally if matching
primers were added to the chip. These variants comprise 47/
292 (16%) of all pathologic USH variants. Second, the screening
costs, including development costs, are quite high, prohibiting
the use of this technique in a routine laboratory setting.
A direct comparison of efficiency with other mutation
detection techniques is not straightforward since no compre-
hensive mutation detection studies have yet been performed for
more than one Usher gene. For USH1, the most commonly used
technique is single strand conformation polymorphism (SSCP)
analysis, which yielded between 19% and 48% of mutant alleles
in MYO7A,32 33 43 which is comparable to our overall efficiency
(31% of alleles; table 2). For USH2, SSCP and sequence analysis
of exons 1–21 of USH2A yielded 23% and 38% of mutant alleles,
respectively,17 38 which is higher than with the APEX technology
(18%). The relatively low yield of USH2 alleles is due to the fact
that the USH2A gene was expanded only recently from 21 to 73
exons39 and because comprehensive mutation analysis of this
gene lags behind MYO7A.
Thus, efficiencies for the Usher chip at the moment can be
best compared to the recently developed APEX chip for LCA,
which is comparable in complexity (contains ,300 variants
found in seven genes) and yields on average 20–28% of LCA
alleles.25 26 The Usher microarray chip is particularly useful for
the analysis of patients with USHA, who have been shown to
carry mutations in the MYO7A, CDH23 and USH2A genes.
The overall efficiency of the Usher chip in the future is
expected to increase in proportion to the addition of new
variants. We propose the use of this mutation chip as a first-
pass screening tool for all Usher patients. In patients with one
or no variant, capillary-based heteroduplex analysis of the
larger genes (CDH23, MYO7A, PCDH15, USH1C, USH2A, VLGR1)
or sequence analysis of the smaller genes (USH1G, USH3A) can
be performed. Novel variants from these studies can subse-
quently be added to the chip, resulting in a gradual increase in
its efficiency. The Usher syndrome mutation detection chip can
be obtained from Asper Ophthalmics (Tartu, Estonia; http://
www.asperophthalmics.com/UshersyndromeDNAtest.htm).
Table 4 Usher syndrome patients with sequence variants in two Usher genes
Patient Phenotype Allele 1 Allele 2 Allele 3
Val-1 USH1 CDH23 p.R2833G MYO7A p.R302H
Val-2 USH1 MYO7A p.A1340T USH1C p.R80fs
Val-4 USH2 USH2A p.C1002fs MYO7A p.R302H
H0151 USH2 USH2A p.C419F MYO7A p.E1359fs
H0165 USH2 USH2A p.R317R MYO7A p.T1566M
H2264 USH2 USH2A p.E767fs MYO7A p.R1743W
Val-3 USH2 USH2A p.K182fs USH2A p.E767fs MYO7A p.R1343S
H0900 USH2 USH2A p.V218E USH2A p.W3955X MYO7A p.T165M
P99-0345 USH1 MYO7A p.Q121fs MYO7A p.Q121fs USH1C p.P608R
Table 5 A comparison of mutation detection techniques for Usher syndrome
Advantages Disadvantages
APEX Robust Detects only known variants
Versatile (addition of new variants with little extra costs) Low efficiency in early stages
Cheap (,J200) Less efficient for analysing patients of other ethnic backgrounds
Medium throughput Requires specialised expertise
Not highly dependent on DNA quality Sequence confirmation required
Sequence analysis Robust High costs (.J1000 for MYO7A or USH2A)
Versatile
Easy set-up
Capillary-based heteroduplex Robust Polymorphic sequences difficult to analyse
analysis Medium throughput Sequence analysis necessary for mutation identification
Relatively cheap
Resequencing (Affymetrix) Fully automated High costs (,J600)
Detects known and new nucleotide substitutions No detection of heterozygous deletions .1 nt and all duplications/
insertions (47/292 (16%) pathologic USH variants)
Addition of tested genes requires new chip design
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Deficiencies in the Usher chip and other conventionally
used mutation detection techniques
Currently, none of the standard mutation analysis techniques is
able to identify heterozygous deletions that span one or both
amplicon primers. As a result, we have no knowledge
whatsoever about the frequency of deletions of this kind.
Therefore, a customised probe set needs to be designed that can
identify copy-number changes, for example, multiplex ligation
dependent probe amplification or quantitative PCR.44 Likewise,
deep intronic mutations affecting splicing are missed as RNA
analyses are not part of standard procedures due to restricted
expression of the Usher genes.
Pathogenicity of variants in Usher genes
When a known mutation is detected in both copies of one of the
Usher genes, one can confidently conclude that these mutations
are disease-causing. Two alleles were found in 24/140 (17%)
USH1 patients, 9/85 (11%) USH2 patients, 2/21 (10%) USH3
patients and 2/20 (10%) USHA patients. However, when one
mutated allele is observed, the chance that a false conclusion is
made regarding causality of this particular variant for the
phenotype in that patient, differs for each of the Usher
syndrome genes. For the MYO7A gene in USH1 patients, the
percentage of patients with a false interpretation based on the
presence of one mutated allele for this gene was calculated to
be 2.4; for the USH2A gene in USH2 patients, this percentage
was calculated to be 0.8.45 For diagnoses based on one allele
with a missense mutation, this percentage is likely to be higher
due to the fact that the pathogenicity of this type of mutation is
difficult to prove. Due to the small sizes of the families with
Usher syndrome and the fact that samples of other family
members are often not available, it is mostly not possible to
perform segregation analysis to prove the pathogenicity of a
specific sequence variant.
We also included on the microarray a number of sequence
variants that we assume are not pathogenic. The results in the
present study support this assumption. However, it cannot be
excluded that these variants can modulate the disease severity
in a way comparable to that of a sequence variant in Bardet-
Biedl syndrome. An exonic nucleotide substitution that affects
splicing of the MGC1203 RNA modulates the phenotype of
patients with Bardet-Biedl syndrome with mutations in the
BBS1 gene because the BBS1 and MGC1203 proteins interact.46
Since both the USH1 and USH2 proteins are known be part of
an Usher interactome,47–52 phenotypic modulation might well be
possible and was already suggested in a family with homo-
zygous USH3A mutations in the affected members and a
mutated MYO7A gene in one of them.53 54
Digenic inheritance in Usher syndrome?
Since Usher proteins interact with each other and form
dynamic protein complexes, digenic or oligogenic inheritance
of Usher syndrome would not be surprising. Indications for
digenic inheritance involving mutations in the PCDH15 and
CDH23 genes have been obtained for two USH1 patients and a
patient with USHA,55 but no elaborate segregation analysis was
reported to strengthen this observation. The large number of
patient DNAs screened in the present study is specifically
suitable for detection of rare cases exhibiting digenic inheri-
tance of the syndrome. From the nine cases with sequence
variants in two different genes, one is unlikely to follow digenic
inheritance since two truncating mutations in one of the genes
were present. PCDH15 and CDH23, previously implicated in
digenicity, were not involved in any of the remaining eight
cases. Segregation analysis could not be performed for any of
the cases and therefore, we cannot confirm or exclude digenic
inheritance.
Use of the Usher microarray for patients with non-
syndromic arRP and hearing impairment
Mutations in the USH2A gene have been described to be a
common cause of RP and the p.C759F mutation is almost
exclusively detected in patients with non-syndromic RP. Based
on their results of screening exons 1–21 of the gene, Jian
Seyedahmadi et al17 estimated that USH2A mutations are
present in 7% of all RP cases in the USA and screening of
only one third of exons 22–73 increased this to 16% for arRP
patients.56 Since all USH2A mutations detected in RP patients
are represented on the Usher microarray, this is also suitable for
this patient population. However, a mutation array with known
mutations in a large number of RP genes, including USH2A, has
been developed57 and is more suitable for mutation detection in
patients with RP.
Mutations in the USH1 genes CDH23 (DFNB12), MYO7A
(DFNA11, DFNB2), PCDH15 (DFNB23) and USH1C (DFNB18)
can cause non-syndromic hearing loss.51 Among these genes,
CDH23 seems to be the most frequently involved in non-
syndromic hearing loss. The hearing loss in DFNB12 patients
ranges from moderate to profound, but also patients with hearing
loss that started as mild in childhood have been described to have
mutations in CDH23.20 So far, there are no indications that
mutations in the USH1 genes are a common cause of non-
syndromic hearing loss. However, more extensive mutation
analysis in this patient category is necessary to determine the
value of the present microarray for this group of patients.
ELECTRONIC DATABASE INFORMATION
The UCSC Human Genome Browser is at http://genome.
cse.ucsc.edu, the Asper Biotech website is at http://www.
asperbio.com and the Asper Ophthalmics web site is at http://
www.asperophthalmics.com/UshersyndromeDNAtest.htm
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